Endoscopic eradication therapy for mucosal neoplasia in Barrett's esophagus

Current Opinion in Gastroenterology

Volumn 29, Issue 4, 2013, Pages 446-453

  Dunbar, Kerry B ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Barrett's esophagus; cryotherapy; dysplasia; endoscopic mucosal resection; radiofrequency ablation

Indexed keywords

ACETYLCYSTEINE; CARBON DIOXIDE; LIQUID NITROGEN; PROTON PUMP INHIBITOR;

ALTERNATIVE MEDICINE; ARGON PLASMA COAGULATION; BARRETT ESOPHAGUS; BARRETT ESOPHAGUS NEOPLASIA; CANCER RISK; CANCER SURGERY; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; EARLY CANCER; ENDOSCOPIC MUCOSAL RESECTION; ENDOSCOPIC SUBMUCOSAL DISSECTION; ENDOSCOPIC THERAPY; ERADICATION THERAPY; ESOPHAGUS CANCER; ESOPHAGUS MUCOSA; ESOPHAGUS RESECTION; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DYSPLASIA; HUMAN; INTESTINE METAPLASIA; LYMPH NODE METASTASIS; PATIENT SELECTION; RADIOFREQUENCY ABLATION; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; TREATMENT FAILURE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CATHETER ABLATION; CRYOSURGERY; ESOPHAGEAL NEOPLASMS; ESOPHAGOSCOPY; HUMANS; NEOPLASM RECURRENCE, LOCAL; PRECANCEROUS CONDITIONS;

EID: 84879940239     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283622848     Document Type: Review

References (32)

1. Heuberger D, Manner H, Ell C, Pech O. How is early Barrett's cancer currently diagnosed and treated in Western Europe? Results of a survey at 52 university hospitals in eight Western European countries. Z Gastroenterol 2012; 50:670-676.
2. Dunn JM, Mackenzie GD, Banks MR, et al. A randomised controlled trial of ALA vs. photofrin photodynamic therapy for high-grade dysplasia arising in Barrett's oesophagus. Lasers Med Sci 2013; 28:707-715.
3. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011; 140:e18-e52.
4. Alvarez Herrero L, Pouw RE, van Vilsteren FG, et al. Safety and efficacy of multiband mucosectomy in 1060 resections in Barrett's esophagus. Endo-scopy 2011; 43:177-183.
5. Chung A, Bourke MJ, Hourigan LF, et al. Complete Barrett's excision by stepwise endoscopic resection in short-segment disease: long term out-comes and predictors of stricture. Endoscopy 2011; 43:1025-1032.
6. Greenwald BD, Dumot JA, Abrams JA, et al. Endoscopicspraycryo therapy for esophageal cancer: safetyand efficacy. Gastrointest Endosc 2010; 71:686-693.
7. Greenwald BD, Dumot JA, Horwhat JD, et al. Safety, tolerability, and efficacy of endoscopic low-pressure liquid nitrogen spray cryotherapy in the esopha-gus. Dis Esophagus 2010; 23:13-19.
8. Shaheen NJ, Greenwald BD, Peery AF, et al. Safety and efficacy of endo-scopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc 2010; 71:680-685.
9. Guarner-Argente C, Buoncristiano T, Furth EE, et al. Long-term outcomes of patients with Barrett's esophagus and high-grade dysplasia or early cancer treated with endoluminal therapies with intention to complete eradication. Gastrointest Endosc 2013; 77:190-199.
10. Bulsiewicz WJ, Kim HP, Dellon ES, et al. Safety and efficacy of endoscopic mucosal therapy with radiofrequency ablation for patients with neoplastic barrett's esophagus. Clin Gastroenterol Hepatol 2012. [Epub ahead of print].
11. Akiyama J, Marcus SN, Triadafilopoulos G. Effective intra-esophageal acid control is associated with improved radiofrequency ablation outcomes in Barrett's esophagus. Dig Dis Sci 2012; 57:2625-2632.
12. Krishnan K, Pandolfino JE, Kahrilas PJ, et al. Increased risk for persistent intestinal metaplasia in patients with Barrett's esophagus and uncontrolled reflux exposure before radiofrequency ablation. Gastroenterology 2012; 143:576-581.
13. Titi M, Overhiser A, Ulusarac O, et al. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency abla-tion of Barrett's esophagus. Gastroenterology 2012; 143:564-566.
14. Gray NA, Odze RD, Spechler SJ. Buried metaplasia after end oscopicablation of Barrett's esophagus: a systematic review. Am J Gastroenterol 2011; 106:1899-1908.
15. Orman ES, Kim HP, Bulsiewicz WJ, et al. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation. Am J Gastroenterol 2013; 108:187-195.
16. Korst RJ, Santana-Joseph S, Rutledge JR, et al. Patterns of recurrent and persistent intestinal metaplasia after successful radiofrequency ablation of Barrett's esophagus. J Thorac Cardiovasc Surg 2012. [Epub ahead of print].
17. Shaheen NJ, Overholt BF, Sampliner RE, et al. Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology 2011; 141:460-468.
18. Halsey KD, Chang JW, Waldt A, Greenwald BD. Recurrent disease following endoscopic ablation of Barrett's high-grade dysplasia with spray cryotherapy. Endoscopy 2011; 43:844-848.
19. Okoro NI, Tomizawa Y, Dunagan KT, et al. Safetyofpriorendoscopic mucosal resection in patients receiving radiofrequency ablation of Barrett's esopha-gus. Clin Gastroenterol Hepatol 2012; 10:150-154.
20. Kim HP, Bulsiewicz WJ, Cotton CC, et al. Focal endoscopic mucosal resection before radiofrequency ablation is equally effective and safe com-pared with radiofrequency ablation alone for the eradication of Barrett's esophagus with advanced neoplasia. Gastrointest Endosc 2012; 76:733-739.
21. van Vilsteren FG, Alvarez Herrero L, Pouw RE, et al. Radiofrequency ablation and endoscopic resection in a single session for Barrett's esophagus contain-ing early neoplasia: afeasibilitystudy. Endoscopy 2012; 44:1096-1104.
22. Neuhaus H, Terheggen G, Rutz EM, et al. Endoscopic submucosal dissection plus radiofrequency ablation of neoplastic Barrett's esophagus. Endoscopy 2012; 44:1105-1113.
23. van Vilsteren FG, Phoa KN, Herrero LA, et al. Circumferential balloon-based radiofrequency ablation of Barrett's esophagus with dysplasia can be simplified, yet efficacy maintained, by omitting the cleaning phase. Clin Gastroenterol Hepatol 2013; 11:491-498.
24. Hur C, Choi SE, Rubenstein JH, et al. The cost effectiveness of radiofrequency ablation for Barrett's esophagus. Gastroenterology 2012; 143: 567-575.
25. Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011; 365:1375-1383.
26. Sharma P, Falk GW, Weston AP, et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006; 4:566-572.
27. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011; 103:1049-1057.
28. Dunbar KB, Spechler SJ. The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus: a systematic review. Am J Gastroenterol 2012; 107:850-862.
29. Gockel I, Sgourakis G, Lyros O, et al. Risk of lymph node metastasis in submucosal esophageal cancer: a review of surgically resected patients. Expert Rev Gastroenterol Hepatol 2011; 5:371-384.
30. Tian J, Prasad GA, Lutzke LS, et al. Outcomes of T1b esophageal adeno-carcinoma patients. Gastrointest Endosc 2011; 74:1201-1206.
31. Alvarez Herrero L, Pouw RE, van Vilsteren FG, et al. Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy 2010; 42:1030-1036.
32. Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012; 143:336-346.